Viet Le, DMSc, PA-C, is a preventive cardiology PA at Intermountain Health and the former president of the Academy of Physician Associates in Cardiology.

Conference Preview: American Heart Association Scientific Sessions 2025, With Viet Le, DMSc, PA-C

The American Heart Association (AHA) Scientific Sessions 2025

 kicks off in New Orleans, Louisiana, on November 7, 2025, and will spotlight some of the most impactful developments in cardiology this year. With hundreds of presentations slated over the 4-day meeting, keeping up with all the trial results and treatment advancements can be challenging.

 spoke with Viet Le, DMSc, PA-C, to discuss his top 5 trials to watch during the conference. From gene editing with CRISPR to caffeine’s effects on atrial fibrillation, Le highlights key data and upcoming therapies he believes may redefine cardiovascular care.


1. DR10624 Rapidly and Significantly Reduced Triglycerides, Atherogenic Lipids, and Liver Fat in Patients with Severe Hypertriglyceridemia: Primary Results from a Randomized Phase 2 Trial

: Saturday, November 8, 8:30 - 8:40 am CST


: DR10624 is a combination GLP-1 receptor/glucagon receptor/fibroblast growth factor 21 receptor (FGF21R) agonist under investigation for severe hypertriglyceridemia. This multicenter, randomized, double-blind, placebo-controlled phase 2 clinical study saw patients randomly assigned into 3 experimental cohorts, each of which was then assigned to either a DR10624 injection or placebo. The primary outcome was a change in fasting triglyceride (TG), and secondary outcomes included changes in lipid and lipoprotein profiles, change of glycosylated hemoglobin, and change of liver fat content, among others.

2. First-in-Human Phase 1 Clinical Trial of a CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 & In Vivo Gene Editing of Angiotensin in Hepatocytes Safely and Potently Reduces Blood Pressure in Preclinical Models

: Saturday, November 8, 8:56 – 9:06 am CST | Saturday, November 8, 2:30 – 3:30 pm CST


: Stephen Nicholls, MBBS, PhD | Kenny Drombosky, PhD


: CTX310 targets ANGPTL3, a gene encoding for proteins involved in regulating LDL and TG levels. CRISPR Therapeutics is actively testing it in combatting loss-of-function mutations in ANGPTL3, which are a recognized risk factor for 

atherosclerotic cardiovascular disease (ASCVD)

 due to their significant reduction of LDL and TG. The gene therapy is in an ongoing phase 1 first-in-human trial across 4 patient groups: homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia, severe hypertriglyceridemia, and mixed 

. This presentation will collect the complete phase 1 data, building on a previous release of data on the first 10 participants.

CRISPR will also be presenting preclinical data on CTX340, another experimental program targeting angiotensin for the treatment of refractory 

. This treatment makes use of the company’s proprietary lipid nanoparticle, the in vivo editing platform.

: Saturday, November 8, 1:30 – 1:45 pm CST


: This landmark phase 3 trial met its dual primary endpoints of time to first occurrence of a composite of coronary heart disease death, heart attack, or ischemic stroke, and time to first occurrence of a composite of coronary heart disease death, heart attack, ischemic stroke, or any ischemia-driven arterial revascularization on October 2, 2025. Evolocumab substantially reduced the risk of major adverse cardiovascular events in patients without a prior history of heart attack or stroke.

As announced by parent company Amgen, this presentation will provide the complete results from the trial.

4. Dapagliflozin to Reduce Atrial Fibrillation Burden After Catheter Ablation for Atrial Fibrillation in Patients Without Diabetes or Heart Failure: The DARE-AF Randomized Clinical Trial

: Sunday, November 9, 8:15 – 8:25 am PST


: DARE-AF was a single-center, parallel-group, randomized, open-label trial evaluating the SGLT2 inhibitor dapagliflozin 10 mg once daily over 3 months on the recurrence of atrial fibrillation after catheter ablation for patients without 

. Patients were randomly assigned to either dapagliflozin or no intervention, with a primary outcome of atrial fibrillation burden at 3 months. With the trial completed, the data to be presented at AHA 2025 may indicate another potential treatment pathway for dapagliflozin, and potentially SGLT2 inhibitors in general, in cardiology.

5. The Does Eliminating Coffee Avoid Fibrillation (DECAF) Trial

 Sunday, November 9, 8:45 – 8:55 am PST


: The effects of caffeine on atrial fibrillation have been debated in cardiology for some time; given the widespread consumption of coffee and the increasing population impact of atrial fibrillation, determining an associated benefit or risk is becoming more clinically relevant. The DECAF study was a randomized evaluation of coffee on atrial fibrillation outcomes by following 2 patient groups, with 1 assigned to abstain from caffeinated beverages and 1 assigned to drink coffee regularly, with a recommended average of ≥1 shot of espresso or caffeinated coffee per day. These data will answer a longstanding and increasingly relevant question in the cardiovascular field, making it a presentation not to be missed.

Zhejiang Doer Biologics Co., Ltd. A Phase II Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Severe Hypertriglyceridemia. ClinicalTrials.gov identifier: NCT06555640. Updated August 19, 2024. Accessed October 30, 2025. 

https://clinicaltrials.gov/study/NCT06555640

CRISPR Therapeutics. CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310 Targeting ANGPTL3. May 6, 2025. Accessed October 30, 2025. 

https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-provides-first-quarter-2025-financial

CRISPR Therapeutics. CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025. September 9, 2025. Accessed October 30, 2025. 

https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-present-late-breaking-data-american-heart

Amgen. Landmark Phase 3 Trial (VESALIUS-CV) Meets Primary Endpoints in a Cardiovascular Primary Prevention Study of 12,000 Patients. October 2, 2025. Accessed October 30, 2025. 

https://www.amgen.com/newsroom/press-releases/2025/10/landmark-phase-3-trial-vesaliuscv-meets-primary-endpoints-in-a-cardiovascular-primary-prevention-study-of-12000-patients

Beijing Anzhen Hospital. Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation (DARE-AF). ClinicalTrials.gov identifier: NCT06433479. Updated July 15, 2025. Accessed October 30, 2025. 

https://clinicaltrials.gov/study/NCT06433479

University of California, San Francisco. Does Eliminating Coffee Avoid Fibrillation? (DECAF). ClinicalTrials.gov identifier: NCT05121519. Updated October 24, 2025. Accessed October 30, 2025. 

https://clinicaltrials.gov/study/NCT05121519

Videos

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Dyslipidemia

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Atherosclerotic Cardiovascular Disease

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Achieving “State Zero”: New Data on Bimekizumab, Other IL-17is, Transform PsA Treatment Goals, with Philip Mease, MD

Interleukin-17 (IL-17) inhibition continues to evolve as a major frontier in psoriatic arthritis (PsA) treatment, with new data on both approved and investigational therapies recently presented at the 

American College of Rheumatology (ACR) Convergence 2025

, held October 24–29 in Chicago, Illinois, by Philip Mease, MD, Clinical Professor at the University of Washington and Director of Rheumatology Research at the Swedish Medical Center in Seattle.

Mease spoke about key findings on several IL-17 targeting agents, bimekizumab, sonelokimab, and izokibep, that are shaping current and future management strategies for PsA. 

New data on bimekizumab, a dual IL-17a/17f inhibitor, reinforce the importance of achieving complete remission across clinical domains, or "state zero." Mease and colleagues found that when patients reach “state zero”—meaning full resolution of manifestations such as swollen joints, enthesitis, or radiographic progression—they experience substantial parallel improvements in pain, function, and overall quality of life. 

Meanwhile, new phase 2 data on sonelokimab, a nanobody IL-17A and IL-17F inhibitor, demonstrated that at 24 weeks, more than half of treated patients achieved major composite outcomes such as ACR50 and minimal disease activity, with responses spanning key domains of arthritis, enthesitis, and skin involvement.

Lastly, Mease discussed 1-year outcomes from izokibep, a small molecule IL-17A inhibitor with a compact protein scaffold design, which demonstrated durable efficacy through 52 weeks. Patients maintained high rates of ACR50 responses, functional improvement, and sustained low disease activity, suggesting that next-generation small molecule constructs may rival biologics in depth and durability of response.

Mease's disclosures include AbbVie, ACELYRIN, Amgen, Bristol Myers Squibb, Century Therapeutics, Cullinan Biotech, Eli Lilly, Genascence, GRAPPA, Immagene, Johnson & Johnson, MoonLake Immunotherapeutics, Novartis, OMERACT, Pfizer, SPARTAN, Takeda, and UCB Pharma.

Mease PJ, Poddubnyy D, Bajracharya R, et al. Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies. Presented at: ACR Convergence 2025; October 24-29; Chicago, Illinois. Poster #1454

Mease PJ, Gossec L, Deodhar A, et al. Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design. Presented at: ACR Convergence 2025; October 24-29; Chicago, Illinois. Poster #1455

Mease PJ, Behrens F, Kivitz AJ, et al. Efficacy and Safety of Izokibep, a Novel IL-17A Inhibitor, in Patients with Active Psoriatic Arthritis: Week 52 Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b/3 Study. Presented at: ACR Convergence 2025; October 24-29; Chicago, Illinois. Poster #LB08

Mease discussed the latest updates on bimekizumab, sonelokimab, and izokibep at ACR Convergence 2025.

Psoriatic Arthritis

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Marlyn Mayo, MD, is a professor of internal medicine at UT Southwestern Medical Center.

Seladelpar’s Impact on Pruritus in Primary Biliary Cholangitis, With Marlyn Mayo, MD

Primary biliary cholangitis (PBC) remains a challenging chronic liver disease in which symptom management is just as important as controlling biochemical markers of disease activity. Among the most burdensome symptoms is pruritus, which affects the majority of patients and can severely diminish quality of life, yet often goes underrecognized and undertreated in clinical practice.

As new therapies emerge, the treatment landscape for PBC is undergoing rapid change, offering clinicians and patients renewed hope for both disease control and symptom relief. Against this backdrop, recent data on the selective PPAR-delta agonist seladelpar presented at the 

American College of Gastroenterology (ACG)’s 2025 Annual Scientific Meeting

 by Marlyn Mayo, MD, a professor of internal medicine at UT Southwestern Medical Center, are providing important insight into how modern therapies can address not only biochemical response but also the persistent challenge of itch in PBC.

, Mayo emphasized that following Intercept Pharmaceuticals’ recent voluntary withdrawal of obeticholic acid from the US market, an influx of patients will need to find a new second-line therapy, raising questions about how clinicians will use the 2 currently available options and their impact on itch.

“One of the things that I presented was the characteristics in the [seladelpar] phase 3 study of itching, and it was very striking to me that only 25% of the patients who put on the questionnaires that they had moderate to severe itch were actually getting any kind of therapy for their itch, which goes to show you how bad we are at treating that symptom, even in centers that are doing research in PBC that are supposed to be centers of excellence,” Mayo said, referencing findings from a pooled post-hoc analysis of pruritus outcomes from the RESPONSE and ENHANCE trials.

Of the 126 participants in the trials with moderate to severe pruritus, 76 and 50 pts received seladelpar 10 mg and placebo, respectively, in RESPONSE or ENHANCE. At baseline, most patients were < 50 years of age at the time of PBC diagnosis (n = 73) and had a history of pruritus (n = 122) and fatigue (n = 77).

Data presented at ACG showed that at 6 months, compared with placebo, patients who received seladelpar experienced greater improvements in NRS scores (mean change from baseline, −3.12 vs −2.09; 

 = .0004), PBC-40 itch domain scores (mean change from baseline, −2.26 vs −1.37; 

 = .0227), 5-D itch total scores (mean change from baseline, −4.85 vs −2.30; 

 <.0001), and 5-D itch degree domain scores (mean change from baseline, −0.96 vs −0.54; 

 = .0005). Of note, the safety profiles in patients with pruritus in the seladelpar and placebo groups were similar, with adverse events occurring in 76.3% of seladelpar patients and 80% of placebo patients.

While Mayo acknowledged seladelpar’s apparent benefit for relieving itch, she notes that the medication in its currently approved indication “fulfills a very specific niche” for ursodeoxycholic acid nonresponders who experience pruritus. For patients who respond well to ursodeoxycholic acid but still deal with itching, seladelpar is not yet an option.

“This drug is not approved for that indication, and we don't have data in that situation, so I think that is still an unfulfilled need,” Mayo said. “There are drugs that are being studied for that purpose, and hopefully someday we'll have something.”

Editors’ Note: Mayo reports relevant disclosures with CymaBay Therapeutics, GSK, Ipsen, Mirum Pharma, and more.

Jones DEJ, Levy C, Kremer AE, et al. Change in Pruritus in Patients With Primary Biliary Cholangitis and Moderate to Severe Pruritus: A Pooled Analysis From the RESPONSE and ENHANCE Studies. Presented at the American College of Gastroenterology (ACG)’s 2025 Annual Scientific Meeting. Phoenix, Arizona. October 27-29, 2025.

Brooks A. Intercept Voluntarily Withdraws Obeticholic Acid (Ocaliva) for PBC From US Market. HCPLive. September 11, 2025. Accessed October 30, 2025. 

https://www.hcplive.com/view/intercept-voluntarily-withdrawals-obeticholic-acid-ocaliva-for-pbc-from-us-market

Mayo explains findings from a pooled analysis of pruritus data from RESPONSE and ENHANCE highlighting seladelpar’s impact on itch in PBC.

Hepatology

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Mark Nestor, MD, PhD, is the director of the Center for Cosmetic Enhancement and the Center for Clinical and Cosmetic Research in Florida and a voluntary associate professor of the Department of Dermatology and Cutaneous Surgery at the University of Miami, Leonard Miller School of Medicine.

2025 Fall Clinical Dermatology Conference

 in Las Vegas, Nevada, featured a variety of sessions, including 1 titled ‘60 Tips for Better Outcomes: Aesthetic, Regenerative, Hair.’

This session was presented by a variety of experts, including Mark S. Nestor, MD, PhD, the director of the Center for Cosmetic Enhancement and Director of the Center for Clinical and Cosmetic Research in Aventura, Florida. In an on-site interview at Fall Clinical, Nestor touched on some of his portion of the session’s biggest takeaways.

Tips for Better Outcomes in Aesthetic Dermatology, With Mark S. Nestor, MD, PhD

“I talked about the issue of how to avoid cosmetic complications of things like fillers, knowing the anatomy, knowing what to look for if you have a vascular event, is very important,” Nestor explained. “[This is] because you need to treat it very quickly with hyaluronidase, with nitroglycerin paste, and other things as well. So I touched on that as one of my tips.”

In another tip highlighted in this session, Nestor talked about ways to expand one’s cosmetic procedures as a dermatologist.

“I think the beauty is that being a dermatologist, we have a lot of patients coming through our office, which is different than plastic surgeons, and the idea is to educate those patients as to what you can do,” Nestor said. “I can do toxins, I can do fillers, I can do these procedures. Patients are looking for this. They're looking towards our expertise, and that's the best way to really expand this in your practice.”

Nestor was also asked about his session on the science of botulinum toxin use in dermatology practices, also known as Botox.

“There are now a total a number of different toxins,” Nestor explained. “Letybo is the most recent one that's been approved…And the question is, you have reps coming into your office. How do you choose? What I discussed is the issue that, number one, all type A toxins are identical. They work the same way. The difference is what we call molecular potency.”

Molecular potency, Nestor noted, has to do with the number of 150-kilodalton proteins. These are specifically the heavy chains that bind to what is known as the SV2 receptor.

“The more binding that is, the more heavy chains get in, the more light chains get in,” Nestor said. “That's what cleaves the SNAP-25 protein of the trans-SNARE complex; therefore, the acetylcholine vesicles can’t bind, and nothing happens to the muscle. The issue then becomes, how do you get a more robust response?”

What needs to occur, Nestor noted, is a clinician must figure out the ‘molecular potency quotient,’ or what type of effect is desired. If the desired effect is occurring with different toxins, then a lower-cost option may be chosen.

For any further information on Nestor’s sessions at Fall Clinical, view his full interview segment posted above.

In this summary of Nestor's interview, quotes were edited for the purposes of clarity.

Nestor has reported serving as a consultant for Revian.

Nestor M, Ablon G, Weinkle S, et al. 60 Tips for Better Outcomes: Aesthetic, Regenerative, Hair. Session presentation at the 2025 Fall Clinical Dermatology Conference, Las Vegas, Nevada, Oct 23-26, 2025.

Nestor M. The Science of Botulinum Toxin. Session presentation at the 2025 Fall Clinical Dermatology Conference, Las Vegas, Nevada, Oct 23-26, 2025.

Nestor spoke in this interview about avoiding cosmetic complications and educating patients on available treatments like toxins and fillers.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

 Northwestern University Feinberg School of Medicine

Peanut Allergy Rates Plummet 10 Years After AAP Early Introduction Guidelines

sharp decline in peanut and food allergy prevalence

, but experts say the real work is just beginning.

A decade after the American Academy of Pediatrics (AAP) endorsed early peanut introduction, new real-world data suggest those recommendations are paying off.

A study led by David Hill, MD, PhD, and colleagues at the Children’s Hospital of Philadelphia analyzed data from more than 85,000 children across nearly 50 pediatric practices and found a 27% drop in 

 following the 2015 early introduction guidelines (

 <.0001), along with a 43% decrease after the 2017 addendum (

 <.0001). Rates of any IgE-mediated food allergy also fell by more than a third, offering promise for food allergy prevention.

, provide the first large-scale evidence that national policy changes inspired by the landmark LEAP trial have translated into measurable real-world benefits. The LEAP study, published in 2015, demonstrated that infants who were introduced to peanuts early and kept them in their diet were significantly less likely to develop a peanut allergy later in life.

“An outstanding question after these guidelines was whether we are actually seeing meaningful changes in the prevalence of food allergy, and so that is why we did this study,” Stanislaw J. Gabryszewski, MD, PhD, a trial investigator of the recent analysis and an attending physician at Children’s Hospital of Philadelphia, told 

. “Reassuringly, we did see declines in the rates of both peanut and just overall food allergy prevalence.”

Still, despite encouraging data, experts say implementation remains uneven. Previous surveys show that fewer than 1 in 3 pediatricians, and only 17% of caregivers, fully follow the latest recommendations.

Ruchi Gupta, MD, MPH, director of the Center for Food Allergy & Asthma Research at Northwestern University Feinberg School of Medicine, said the declining rates are a promising signal, even if cause and effect cannot yet be confirmed. She had written a commentary on Hill and colleagues’ paper, praising the team for using AAP’s harmonized electronic health record database to capture real-time, practice-based trends in food allergy prevention.

. She added that it is exciting that the analysis showed a lower incidence of peanut allergy in children born after the guidelines were introduced.

For clinicians, the shift in food allergy prevention has been dramatic. “It’s an everyday conversation,” said Vivian P. Hernandez-Trujillo, MD, a pediatric allergist at Nicklaus Children’s Hospital. “I have it multiple times, especially with parents of young children, because it has just swung so much like in the last 10 years.”

Looking ahead, investigators are expanding their focus beyond peanuts. Gupta’s team is conducting a randomized controlled trial of 1800 infants to determine whether early introduction of other common allergens—such as milk, egg, tree nuts, and sesame—can further reduce food allergy rates.

While the peanut allergy decline marks a major step forward, Gupta emphasized that guideline adoption takes time. “Guidelines take a good 10 to 20 years sometimes to go from publication to actually getting into the general public and having an impact. Having a change happen so quickly is great,” she said. “What I suspect is [that] it was a dip, which is great, but we may see some bouncing around until it stabilizes and actually truly shows that we can decrease and turn the tide of peanut allergy in the US.”

Relevant disclosures include Horizon Therapeutics plc for Gabryszewski; Kaleo, Genetech, and Regeneron Healthcare Solutions for Gupta; and Kaleo for Hernandez-Trujillo.

Derman C. Early Peanut Introduction Guidelines Linked to Drop in Food Allergy Rates. HCPLive. October 20, 2025. 

https://www.hcplive.com/view/early-peanut-introduction-guidelines-linked-drop-food-allergy-rates

Gabryszewski SJ, Dudley J, Faerber JA, et al. Guidelines for Early Food Introduction and Patterns of Food Allergy. Pediatrics. Published online October 20, 2025. 

Fleischer DM, Sicherer S, Greenhawt M, et al. Consensus Communication on Early Peanut Introduction and the Prevention of Peanut Allergy in High-risk Infants. Pediatrics. 2015;136(3):600-604.

 doi:https://doi.org/10.1542/peds.2015-2394

Du Toit G, Sayre PH, Roberts G, et al. Effect of Avoidance on Peanut Allergy after Early Peanut Consumption. N Engl J Med. 2016;374(15):1435-1443. 

Gupta RS, Bilaver LA, Togias A. Encouraging Trends in Peanut Allergy Prevention: Real-World Impact of Prevention Guidelines. 

New data show peanut allergy rates have dropped sharply since early introduction guidelines, reducing 27% and 43% after the 2015 and 2017 guidelines, respectively.


Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Laurie Keefer, PhD, is a clinical health psychologist and professor of medicine at Icahn School of Medicine at Mount Sinai.

Keefer emphasizes the importance of treatment satisfaction and health-related quality of life in IBD and reviews findings from ASPIRE-CD.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

HRQoL, Treatment Satisfaction With Risakizumab in ASPIRE-CD, With Laurie Keefer, PhD

Jonathan Graf, MD, professor of Medicine, Division of Rheumatology at the University of California San Francisco

Graf shared his excitement for a potential new first-in-class therapy for rheumatoid arthritis.

Rheumatoid Arthritis

The HCPLive rheumatoid arthritis page is a comprehensive resource for clinical news and insights on arthritis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for RA, and more.

Rosnilimab: A New Era of Upstream RA Disease Control, With Jonathan Graf, MD

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Articles

Study finds non-celiac gluten or wheat sensitivity is more common in women and linked to IBS, anxiety, and depression.

1 in 10 People Without Celiac Disease Report Gluten or Wheat Sensitivity

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Immediate iFR-guided PCI and deferred cardiac stress MRI-guided PCI showed no significant difference, allowing patients to complete treatment in 1 session.

iMODERN: No Difference Between Immediate and Deferred Heart Attack Treatment

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Utilizing Donor Recipient Characteristics To Improve Kidney Allograft Allocation

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

In the CHECK study, a cross-sectional survey of over 10,000 participants, the prevalence of chronic hand eczema (CHE) in the US was highlighted.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

US Prevalence of Chronic Hand Eczema Identified in CHECK Study

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Mepolizumab shows significant real-world benefits in reducing end-organ dysfunction.

Mepolizumab Demonstrates Benefit for End Organ Dysfunction in EGPA and HES

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

This episode covers the recent approval of oral semaglutide for T2D and a pre-specified subanalysis of the SELECT trial.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Diabetes Dialogue: Oral Semaglutide and SELECT at DTM 2025

Walker Redd, MD, is a gastroenterologist and assistant professor of medicine at UNC School of Medicine.

Redd reviews real-world data highlighting low rates of biopsies performed among patients with esophageal food impaction-related emergency department visits.

Closing the Diagnostic Gap in Eosinophilic Esophagitis, With Walker Redd, MD

Switching to an IL-17 inhibitor after TNF inhibitor failure showed no superior benefits for axial spondyloarthritis.

Spondyloarthritis

The HCPLive spondyloarthritis page is a resource for medical news and expert insights on spondylitis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for autoimmune disease, and more.

Latest News

Conference Preview: American Heart Association Scientific Sessions 2025, With Viet Le, DMSc, PA-C

Achieving “State Zero”: New Data on Bimekizumab, Other IL-17is, Transform PsA Treatment Goals, with Philip Mease, MD

Seladelpar’s Impact on Pruritus in Primary Biliary Cholangitis, With Marlyn Mayo, MD

Tips for Better Outcomes in Aesthetic Dermatology, With Mark S. Nestor, MD, PhD

Peanut Allergy Rates Plummet 10 Years After AAP Early Introduction Guidelines